It is of particular concern that PCSK9 inhibitors can antagonize the enhanced effect of PCSK9 on platelet activity, so it is worth considering whether to use PCSK9 inhibitors directly to alter the prognosis of patients with ischemic stroke with increased platelet activity. The gene discussed is PCSK9; the disease is ischemic stroke.